Beclomethasone

Oral inhalation: Maintenance and prophylactic treatment of asthma; includes those who require corticosteroids and those who may benefit from a dose reduction/elimination of systemically-administered corticosteroids. Not for relief of acute bronchospasm

Hypersensitivity to beclomethasone or any component of the formulation; status asthmaticus

Not to be used in status asthmaticus or for the relief of acute bronchospasm.
long-term use has been associated with fluid retention and hypertension; take precaution in heart failure patients, hepatic impairment, including cirrhosis, renal impairment.

Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods.
Osteoporosis:  high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures especially on oral treatment.
Myasthenia gravis: exacerbation of symptoms may occur especially during initial treatment with corticosteroids.
Myocardial infarct (MI): corticosteroids have been associated with myocardial rupture.
Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines.
Bronchospasm: May occur with wheezing after inhalation
Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes.
Kaposi's sarcoma: Case reports shows that prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma .
Diabetes:  May alter glucose production/regulation leading to hyperglycemia.
Gastrointestinal disease: Risk of perforation in patient with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis).
Seizure disorders: case reports show that adrenal crisis can lead to seizure.
Thyroid disease: metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.
Children: Orally-inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients.
Withdraw systemic therapy with gradual tapering of dose, otherwise withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) may occur.

Central nervous system: Agitation, depression, dizziness, dysphonia, headache, lightheadedness, mental disturbances

Dermatologic: Acneiform lesions, angioedema, atrophy, bruising, pruritus, purpura, striae, rash, urticaria

Endocrine & metabolic: Cushingoid features, growth velocity reduction in children and adolescents, HPA function suppression

Gastrointestinal: Dry/irritated nose, throat and mouth, hoarseness, localized Candida or Aspergillus infection, loss of smell, loss of taste, nausea, unpleasant smell, unpleasant taste, vomiting, weight gain

Ocular: Cataracts, glaucoma, intraocular pressure increased

Respiratory: Cough, paradoxical bronchospasm, pharyngitis, sinusitis, wheezing

Miscellaneous: Anaphylactic/anaphylactoid reactions, death (due to adrenal insufficiency, reported during and after transfer from systemic corticosteroids to aerosol in asthmatic patients), immediate and delayed hypersensitivity reactions

Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation.

C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.